Pricing Log in Create free account
Saturday 7 November 2026 Export IGC’s income statement to Excel — free account

IGC Pharma, Inc.

IGC Healthcare Biotechnology

IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.

Revenue
0.00%
EPS
0.00%
Free cash flow
−45.3%
Total debt
+558.3%

Quarter to September 2026, against a year earlier

0.19 0.00 0.00%
Market cap
$22.0M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−16.49
Beneish M
−3.69
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 21.37%

Capital & Financial Ratios $m

Size
Market Cap 21.95
Revenue ttm 1.10
Net income ttm (8.11)
Free cash flow ttm (5.35)
Net debt Q 0.46
Valuation
P/E 0.00
Forward P/E (2.00) (negative: loss-making)
Price / sales 18.89 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.20
Financial health
Current ratio Q 0.42 (below 1: weak)
Debt / equity Q 0.13 (at or below 0.5: strong)
Interest coverage Q (8.30)
Growth
Revenue growth Q 0.00%
Operating income growth Q −1.36% (below 0%: shrinking)
EPS, this year −100.00% (below 0%: weak)
EPS, next year A +20.00% (at or above 15%: strong)
Revenue, next year A −24.63% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +18.29% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 19.3×, against a ten-year median of 19.3×; over the ten years it ranged from −3.4× in 2018 to 185× in 2021.
P/S against its own 10 years 44.50%
10-year low 10-year high
P/B against its own 10 years 72.03%
10-year low 10-year high
EV/Sales against its own 10 years 48.60%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3 1 0 0
Receivables 0 0 0 0
Inventory 3 2 1 1
Other 0 1 1 0
6 4 3 1
2023 2024 2025 Q'26
Payables 1 1 1 2
ST’ Debt — — — 1
Other — — — —
2 2 2 3

Compound Annual Growth %

10y 5y 3y
Sales (16.46%) (20.77%) 47.38%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (8.11%) (24.92%) (35.77%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.02 Actual −0.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 −0.02 −0.02 Met by 0.00
Q1 FY26 −0.02 −0.02 Met by 0.00
Q2 FY26 −0.02 −0.03 Miss by 0.01
Q3 FY26 −0.02 −0.02 Met by 0.00

EPS $

Jun Sep Dec Mar Year
’26 (0.02) (0.02) — (0.02) —
’25 (0.03) (0.02) (0.02) (0.01) (0.09)
’24 (0.04) (0.05) (0.09) (0.04) (0.22)
’23 (0.05) (0.05) (0.04) (0.08) (0.22)
’22 (0.04) (0.09) (0.05) (0.13) (0.30)
’21 (0.05) (0.04) (0.06) (0.07) (0.21)
’20 (0.03) (0.03) (0.04) (0.08) (0.19)
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 0 0 — 0 —
’25 0 0 0 0 1
’24 1 0 0 0 1
’23 0 0 0 0 1
’22 0 0 0 0 0
’21 1 0 0 0 1
’20 2 2 1 0 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) (1) — (1) —
’25 (2) (1) (1) (1) (5)
’24 (1) (2) (2) (1) (5)
’23 (2) (2) (2) (7) (7)
’22 (2) (2) (2) (7) (7)
’21 (4) (2) (2) (11) (11)
’20 (3) (2) (2) (9) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (1) (2) — (1) —
’25 (2) (1) (1) (1) (5)
’24 (1) (2) (2) (1) (6)
’23 (2) (1) (2) (7) (7)
’22 (2) (2) (2) (8) (8)
’21 (5) (3) (2) (12) (12)
’20 (4) (2) (4) (13) (13)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 1 2 5 4 1 0 1 1 1 1 (16.4%) 1 1 — (13.2%)
Gross margin, % 13.25 37.59 3.74 2.58 2.82 12.58 48.87 48.52 54.50 48.70 23.89 +35.4 pt
EBT (3) (2) (2) (4) (7) (9) (15) (12) (13) (7) (9) +10.8%
EBT margin, % (44.50) (316.75) (81.44) (80.04) (179.64) (981.18) (3,782.37) (1,263.01) (966.54) (560.27) (836.06) (515.8) pt
Net income (3) (2) (2) (4) (7) (9) (15) (12) (13) (7) (8) +10.8%
Per share, $
Per share, $ Revenue 0.39 0.02 0.08 0.14 0.10 0.02 0.01 0.02 0.02 0.02 0.01 (29.6%)
Earnings (0.17) (0.07) (0.06) (0.12) (0.19) (0.21) (0.30) (0.22) (0.22) (0.09) (0.09) (6.6%)
Cash flow (0.01) (0.05) (0.07) (0.09) (0.22) (0.26) (0.15) (0.13) (0.09) (0.06) (0.05) +23.2%
Capex (0.01) (0.01) (0.01) 0.00 (0.11) (0.04) (0.01) 0.00 (0.01) (0.01) 0.00 (2.8%)
Free cash flow (0.02) (0.06) (0.08) (0.10) (0.33) (0.29) (0.16) (0.14) (0.10) (0.07) (0.05) +16.7%
Book value 0.85 0.29 0.29 0.95 0.67 0.78 0.48 0.28 0.12 0.08 0.06 (22.8%)
Shares, m 16 26 28 35 39 42 50 53 59 77 100 +18.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 1.34 20.78 6.88 13.97 4.75 83.65 119.63 19.62 21.00 18.18 18.89 31.0
P/B 0.61 1.64 1.87 2.13 0.73 2.29 1.99 1.20 3.86 3.65 3.20 2.0
EV/Sales 1.26 21.42 6.32 8.99 1.85 68.00 93.65 16.25 20.31 18.07 19.31 25.6
EV/FCF (33.41) (5.79) (4.08) (8.18) (0.32) (2.76) (2.48) (1.18) (4.69) (4.38) (3.73) (6.7)
Cash, $m
Cash, $m Operating cash flow 0 (1) (2) (3) (9) (11) (7) (7) (5) (5) (5) +46.1%
Capex 0 0 0 0 (4) (2) (1) 0 0 0 0 +15.4%
Free cash flow 0 (2) (2) (3) (13) (12) (8) (7) (6) (5) (5) +38.5%
Balance, $m
Balance, $m Working capital 1 2 1 26 16 21 13 5 1 1 (2) (0.1%)
Net debt 0 0 0 (26) (12) (14) (10) (3) (1) 0 0 (6.0%)
Shareholders’ equity 14 7 8 34 27 33 24 15 7 6 7 (8.4%)
Returns, %
Returns, % ROA (14.33) (12.39) (16.14) (18.08) (23.06) (27.17) (47.90) (52.29) (96.01) (76.37) (94.55) (62.0) pt
ROIC (13.48) (16.95) (13.18) (36.22) (29.12) (29.07) (71.03) (61.80) (97.82) (76.81) (90.48) (63.3) pt
ROE (19.57) (17.53) (23.17) (19.68) (24.34) (29.70) (52.97) (59.30) (116.95) (104.33) (126.16) (84.8) pt
People
People Employees 65 31 26 20 50 50 52 61 67 70 — +0.8%
Revenue/emp, $m 0.10 0.02 0.08 0.26 0.08 0.02 0.01 0.01 0.02 0.02 — (17.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

IGC Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CVM Cel-Sci Corporation $24.1M — (loss-making) — (loss-making) −62.66% (below 0%: shrinking) n/m −2.33% (below 0%: shrinking) 0.00% 0.00% Compare
CELU Celularity, Inc. $23.5M — (loss-making) — (loss-making) −5.30% (below 0%: shrinking) n/m −10.91% (below 0%: shrinking) 56.79% (78.00%) Compare
NXTC NextCure, Inc. $23.4M — (loss-making) — (loss-making) +1,549.08% (above 0%: growing) n/m +57.23% (above 0%: growing) 0.00% 0.00% Compare
EVAX Evaxion A/S - Sponsored ADR $23.0M — (loss-making) — (loss-making) +14,590.20% (above 0%: growing) n/m −56.70% (below 0%: shrinking) 100.00% 0.00% Compare
IGC IGC Pharma, Inc. $22.0M — (loss-making) — (loss-making) 0.00% n/m −45.33% (below 0%: shrinking) 18.60% (588.72%)
CRVO CervoMed Inc. $21.9M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −6.20% (below 0%: shrinking) 100.00% 0.00% Compare
FLNA Cassava Sciences, Inc. $21.8M — (loss-making) — +1,328.04% (above 0%: growing) n/m +21.65% (above 0%: growing) 0.00% 0.00% Compare
MCRB Seres Therapeutics, Inc. $20.8M — (loss-making) — (loss-making) +68.95% (above 0%: growing) n/m −576.66% (below 0%: shrinking) 100.00% (2,723.78%) Compare
ATOS Atossa Therapeutics, Inc. $20.2M — (loss-making) — −94.28% (below 0%: shrinking) n/m −32.86% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $22.5M — — +31.83% — −8.55% 28.40% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.89m 1.62m 82,000.00
2024 1.82m 2.70m 118,000.00

Ownership

Directors and executive officers, together 12.00%
Bradbury Strategic Fund 15.20%
Ram Mukunda 6.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

IGC Pharma, Inc. (IGC) Latest News

13 Oct

Impact 4 · · ACCESS Newswire

28 Sep

Impact 3 · · ACCESS Newswire

17 Aug

Impact 4 ·

11 Aug

Impact 4 ·

29 Jul

Impact 3 ·

23 Jun

Impact 4 · · ACCESS Newswire

11 Jun

Impact 3 ·

9 Jun

Impact 3 · · ACCESS Newswire

2 Jun

Impact 3 · · ACCESS Newswire

19 May

Impact 4 · · ACCESS Newswire

28 Apr

Impact 3 · · ACCESS Newswire

22 Apr

Impact 3 · · ACCESS Newswire

20 Apr

Impact 4 ·

14 Apr

Impact 4 · · ACCESS Newswire

8 Apr

Impact 4 · · ACCESS Newswire

7 Apr

Impact 3 · · ACCESS Newswire

19 Mar

Impact 4 · · ACCESS Newswire

18 Mar

Impact 3 · · ACCESS Newswire

26 Feb

Impact 3 · · ACCESS Newswire

24 Feb

Impact 3 · · TipRanks

23 Feb

Impact 3 · · ACCESS Newswire

17 Feb

Impact 4 · · ACCESS Newswire

10 Feb

Impact 3 · · ACCESS Newswire

9 Feb

Impact 4 · · ACCESS Newswire

2 Feb

Impact 4 · · ACCESS Newswire

22 Jan

Impact 3 ·

12 Jan

Impact 3 · · ACCESS NewswireHospital ManagementClinical Trials ArenaMarket Exclusive

6 Jan

Impact 3 · · ACCESS Newswire

5 Jan

Impact 4 · · ACCESS Newswire

19 Dec

Impact 4 · · ACCESS Newswire
stockrow.com/IGC · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com